Eidos Therapeutics
Biotechnology, 101 Montgomery St Ste 2550, San Francisco, California, 94104, United States, 11-50 Employees
Who is EIDOS THERAPEUTICS
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The companys singular mission is to improve and prolong t...
Read More
-
Headquarters: 101 Montgomery St Ste 2550, San Francisco, California, 94104, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from EIDOS THERAPEUTICS
Eidos Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Eidos Therapeutics
Allogene Therapeutics
-
201-500
-
$ 1 Million to 5 Million
Beam Therapeutics
-
501-1000
-
$ 50 Million to 100 Million
bluebird bio
-
201-500
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Eidos Therapeutics
Answer: Eidos Therapeutics's headquarters are located at 101 Montgomery St Ste 2550, San Francisco, California, 94104, United States
Answer: Eidos Therapeutics's official website is https://eidostx.com
Answer: Eidos Therapeutics's revenue is $10 Million to $25 Million
Answer: Eidos Therapeutics's SIC: 2836
Answer: Eidos Therapeutics's NAICS: 325414
Answer: Eidos Therapeutics has 11-50 employees
Answer: Eidos Therapeutics is in Biotechnology
Answer: Eidos Therapeutics top competitors include: Allogene Therapeutics , Beam Therapeutics , bluebird bio
Answer: Eidos Therapeutics contact info: Phone number: Website: https://eidostx.com
Answer: Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The companys singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanfords SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month